Ginsenoside F1 Ameliorates Endothelial Cell Inflammatory Injury and Prevents Atherosclerosis in Mice through A20-Mediated Suppression of NF-kB Signaling

Frontiers in Pharmacology
Meng QinXiaobo Sun

Abstract

Atherosclerosis (AS) is a chronic inflammatory disease and endothelial cell injury is the initial event. In this study, we investigated the protective effects of ginsenoside F1 (GF1) on AS and the potential molecular mechanisms of ox-LDL induced endothelial injury. ApoE-/- mice were fed a high fat diet and orally treated with GF1 (50 mg/kg/day) for 8 weeks. Atherosclerotic plaque and LOX-1, TLR4, NF-κB expression levels in the aortic root and inflammatory factor MPO in whole body were measured. The treatment with GF1 induced a remarkable reduction in the atherosclerotic lesion area, LOX-1, TLR4 expression and decreased the MPO distribution. Meanwhile, in vitro study, we confirmed that GF1 treatment greatly increased ox-LDL-injured endothelial cell viability, ameliorated LOX-1, TLR4 expression levels and reduced monocytes adhesion. Protein microarray demonstrated that GF1 significantly inhibited G-CSF, ICAM-1, MIP-1δ, IL-1α, IL-15, IL-16 levels. Mechanistically, the GF1 treatment suppressed the NF-κB nuclear translocation. Furthermore, our data indicated that GF1 significantly increased A20 expression level and A20 siRNA markedly abolished the attenuation of GF1 on NF-κB nuclear translocation and inflammatory factors expression....Continue Reading

References

Mar 10, 2001·Cell·C K Glass, J L Witztum
Jul 30, 2003·Circulation·Christopher R LongoChristiane Ferran
Jun 9, 2007·Circulation Research·Henning Morawietz
Nov 9, 2007·American Journal of Physiology. Renal Physiology·Jesus H DominguezRichard Peterson
Nov 17, 2007·Proceedings of the National Academy of Sciences of the United States of America·Susanne WolfrumJan L Breslow
Jul 16, 2009·Current Vascular Pharmacology·Jian-Ming LüChangyi Chen
Jul 24, 2010·British Journal of Pharmacology·J C McGrathC L Wainwright
Mar 30, 2011·Journal of Cellular Biochemistry·Xiao SunXiao-Bo Sun
May 3, 2011·Nature Reviews. Drug Discovery·Israel F Charo, Rebecca Taub
Nov 9, 2011·Nature Medicine·Christian Weber, Heidi Noels
Mar 7, 2012·Current Pharmaceutical Design·Antonino TuttolomondoGiuseppe Licata
Oct 22, 2015·Journal of the American Chemical Society·Zi-Ru DaiLing Yang
Dec 15, 2015·International Journal of Cardiology·Vedat TiyeriliRené P Andrié
Jan 24, 2016·Proceedings of the National Academy of Sciences of the United States of America·Jevgenia Zilberman-RudenkoEric P Hanson
Feb 27, 2016·The American Journal of Chinese Medicine·Chong-Zhi WangChun-Su Yuan
May 10, 2016·Journal of Ginseng Research·Yu WangWan-Taek Im

❮ Previous
Next ❯

Citations

Nov 2, 2018·Annals of the New York Academy of Sciences·Kunming TianTatsuya Sawamura
Oct 4, 2018·Current Gene Therapy·Cen YanYing-Mei Feng
Oct 4, 2020·Journal of Lipid Research·Jiayan GuoHong Yin
May 18, 2018·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Bin Rui YangSimon Ming-Yuen Lee
Feb 4, 2021·Journal of Lipid Research·Jiayan GuoHong Yin

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
antibody array
Nuclear
nuclear translocation
PCR
electrophoretic mobility shift assay

Software Mentioned

premier primer
SPSS
Image J
IPP
Living Image
Gel Pro

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Cell Adhesion Molecules in AS

Cell adhesion molecules expressed on the vascular endothelium and circulating leukocytes in response to inflammatory stimuli are implicated in atherosclerosis. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.